Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07199894
PHASE3

Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE

Sponsor: Mansoura University

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to compare combination of Solifenacin and MIrabegron in treatment of primary mono-symptomatic nocturnal enuresis in children. It will also learn about the safety of that combination. The main questions it aims to answer are: Does combination of Solifenacin and MIrabegron lower the number of wet nights? What medical problems do participants have when taking combination of Solifenacin and MIrabegron? Researchers will compare the combination to omegapress to see if the combination works better to treat primary mono-symptomatic nocturnal enuresis. Participants will: Take the combination or Omegapress every day for 3 months Visit the clinic once monthly for checkups and tests Keep a diary of their symptoms and the number of wet nights

Official title: A Randomized Controlled Trial Comparing Mirabegron and Solifenacin Combination Therapy Versus Desmopressin Monotherapy in Treatment of Children With Primary Mono-Symptomatic Nocturnal Enuresis

Key Details

Gender

All

Age Range

6 Years - 18 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2024-12-01

Completion Date

2026-02-01

Last Updated

2025-09-30

Healthy Volunteers

No

Interventions

DRUG

Mirabegron (beta3-adrenoceptor agonist), Anticholinergics

Anticholinergic and B3 agonist drugs used for treatment of mono-symptomatic nocturnal enuresis

DRUG

Desmopressin (DDAVP)

ADH analogue in treatment of mono-symptomatic nocturnal enuresis

Locations (1)

Urology and Nephrology center - Mansoura University

Al Mansurah, Egypt